Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azac...

Full description

Bibliographic Details
Main Authors: Matthew E. Tenold, Benjamin N. Moskoff, David J. Benjamin, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
venetoclax (BCL-2 inhibitor)
hypomethylating agent
relapsed/refractory
real-world data
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/full

Similar Items